Sandra Agostini

Dr. Sandra Agostini


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SASandra Agostini
Sandra Agostini
IMIago Henrique Silva Malta
Iago Henrique Silva Malta
RRRafaela Figueiredo Rodrigues
Rafaela Figueiredo Rodrigues
JFJennifer Tavares Jacon Freitas
Jennifer Tavares Jacon Freitas
MLMônica Esselin de Sousa Lino
Mônica Esselin de Sousa Lino
FCFlávia Carvalho
Flávia Carvalho

6 August 2025 in ChemistrySelect
Verified
Journal Article
Open access
SASandra Agostini
Sandra Agostini
BBBruno Arantes Borges
Bruno Arantes Borges
MAMagali Benjamim de Araújo
Magali Benjamim de Araújo
RBRudy Bonfilio
Rudy Bonfilio
The synthesis of cocrystals stands as a promising and compelling strategy within pharmaceutical research and development since cocrystals present an avenue for altering multiple properties of active pharmaceutical ingredients (APIs) without necessitating chemical structural modifications. Given the significance of this topic, this study aimed to review recent pharmaceutical applications of cocrystals by systematically searching and selecting relevant articles from major databases, including Scopus, Web of Science, and SciFinder. We divided the manuscript into distinct subsections, initially addressing the APIs and coformers used, followed by an exploration of the techniques for obtaining cocrystals, and ultimately focusing on the main effects demonstrated by these cocrystals. The research covered ninety‐five different cocrystals obtained from forty‐six APIs and forty‐eight coformers. We observed an increase in publications concerning cocrystals in recent years compared to other solid‐state forms, underscoring the relevance of this topic. Our findings suggest that cocrystallization consistently produces promising outcomes, owing to its potential to resulting in advantageous biopharmaceutical and/or processing properties. Additionally, the methods for obtaining cocrystals are simple, eco‐friendly and applicable to a wide range of compounds, further enhancing their attractiveness for pharmaceutical applications.

6 November 2021 in Polymers
Verified
Journal Article
Open access
PDF file
RRRafaela Figueiredo Rodrigues
Rafaela Figueiredo Rodrigues
JNJuliana Barbosa Nunes
Juliana Barbosa Nunes
SASandra Agostini
Sandra Agostini
PSPaloma Freitas dos Santos
Paloma Freitas dos Santos
JCJuliana Cancino-Bernardi
Juliana Cancino-Bernardi
Vanessa Bergamin Boralli MarquesVanessa Bergamin Boralli Marques
Vanessa Bergamin Boralli Marques
This study offers a novel oral pregabalin (PG)-loaded drug delivery system based on chitosan and hypromellose phthalate-based polymeric nanocomposite in order to treat neuropathic pain (PG-PN). PG-PN has a particle size of 432 ± 20 nm, a polydispersity index of 0.238 ± 0.001, a zeta potential of +19.0 ± 0.9 mV, a pH of 5.7 ± 0.06, and a spherical shape. Thermal and infrared spectroscopy confirmed nanocomposite generation. PG-PN pharmacokinetics was studied after a single oral dose in male Wistar rats. PG-PN showed greater distribution and clearance than free PG. The antinociceptive effect of PG-PN in neuropathic pain rats was tested by using the chronic constriction injury model. The parameter investigated was the mechanical nociceptive threshold measured by the von Frey filaments test; PG-PN showed a longer antinociceptive effect than free PG. The rota-rod and barbiturate sleep induction procedures were used to determine adverse effects; the criteria included motor deficit and sedative effects. PG-PN and free PG had plenty of motors. PG-PN exhibited a less sedative effect than free PG. By prolonging the antinociceptive effect and decreasing the unfavorable effects, polymeric nanocomposites with pregabalin have shown promise in treating neuropathic pain.

30 March 2022 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
CACintia Oliveira Alves
Cintia Oliveira Alves
RNRômulo Dias Novaes
Rômulo Dias Novaes
MBMaria Tereza Carneiro Paschoal Bernardes
Maria Tereza Carneiro Paschoal Bernardes
RGReggiani Vilela Gonçalves
Reggiani Vilela Gonçalves
LSLaíla Pereira da Silva
Laíla Pereira da Silva
FCFlávia Carvalho
Flávia Carvalho
Objective: Psoriasis is a chronic inflammatory skin disorder. Oral or subcutaneous methotrexate (MTX) is a first-line antipsoriatic treatment, whose adverse effects can be observed even at low doses. To minimize systemic side effects, antipsoriatic drugs should be administered topically, since they could permeate the stratum corneum. As liquid crystals with lamellar phase (LP) can be helpful in promoting skin permeation, this work evaluated two MTX-loaded LPs (C1CH and C1CHCE), based on stearic acid, cholesterol and ceramides, like topical treatments for mice with imiquimod-induced psoriasis. Methods: C1CH and C1CHCE were topically administered to mice with imiquimod-induced psoriasis. Dexamethasone cream was used as positive treatment control. Skin histology and inflammation biomarkers were assessed. Key findings: C1CH and C1CHCE exhibited marked immunomodulatory effects and induced extensive microstructural skin remodelling on the epidermis and dermis. These formulations increased keratinization score, epidermis thickness, inflammatory infiltrate, hair follicle hypertrophy and vascular congestion in the dermis. C1CH and C1CHCE also attenuated IL-10 upregulation and upregulated IL-1, IFN-γ, TNF-α and prostaglandin E2 levels, as well as myeloperoxidase, N-acetyl-β-d-glucosaminidase and cyclooxygenase 2 activity compared with untreated psoriatic animals. Conclusion: Although liquid crystals have been reported as good options for carrying topical drugs, they need to be carefully assessed on a case-by-case basis.

1 January 2022 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
SASandra Agostini
Sandra Agostini
VMVictor Lima de Sousa Machado
Victor Lima de Sousa Machado
LVLuciano Sindra Virtuoso
Luciano Sindra Virtuoso
DNDenismar Alves Nogueira
Denismar Alves Nogueira
GPGislaine Ribeiro Pereira
Gislaine Ribeiro Pereira
FCFlávia Chiva Carvalho
Flávia Chiva Carvalho

28 February 2026 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KRKassius de Souza Reis
Kassius de Souza Reis
BBBruno Arantes Borges
Bruno Arantes Borges
ASAna Carolina Marioto Santos
Ana Carolina Marioto Santos
SASandra Agostini
Sandra Agostini
RBRudy Bonfilio
Rudy Bonfilio